These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8199997)

  • 21. Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry.
    Frankfurt OS; Greco WR; Slocum HK; Arbuck SG; Gamarra M; Pavelic ZP; Rustum YM
    Cytometry; 1984 Nov; 5(6):629-35. PubMed ID: 6518938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Studies on nuclear DNA content in bladder cancers using flow cytometry].
    Toyota K
    Hokkaido Igaku Zasshi; 1996 Jan; 71(1):45-53. PubMed ID: 8727374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Flow cytometric analysis of cellular DNA content in epithelial ovarian cancer].
    Arai H; Izumi S; Wada T; Tsutsui F; Yamaoka K; Nozawa S
    Nihon Rinsho; 1992 Oct; 50(10):2439-43. PubMed ID: 1333018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity and progression of renal cell carcinomas as revealed by DNA cytofluorometry and the significance of the presence of polyploid cells.
    Kushima M; Kushima R; Hattori T; Tomoyoshi T
    Urol Res; 1995; 23(6):381-6. PubMed ID: 8788276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer.
    Friedlander ML; Hedley DW; Swanson C; Russell P
    J Clin Oncol; 1988 Feb; 6(2):282-90. PubMed ID: 3276825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [DNA ploidy and results of first line chemotherapy in ovarian cancer patients].
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Debniak J
    Ginekol Pol; 2006 Aug; 77(8):589-96. PubMed ID: 17076189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors.
    Kühn W; Kaufmann M; Feichter GE; Rummel HH; Schmid H; Heberling D
    Gynecol Oncol; 1989 Jun; 33(3):360-7. PubMed ID: 2722063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow and image cytometric DNA ploidy, including 5c exceeding cells, of serous borderline malignant ovarian tumors. Correlation with clinicopathologic characteristics.
    Flezar MS; But I; Kavalar R; Us-Krasovec M
    Anal Quant Cytol Histol; 2003 Jun; 25(3):139-45. PubMed ID: 12882085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of DNA ploidy status in patients with rectal cancer.
    Berczi C; Bocsi J; Bartha I; Math J; Balazs G
    Anticancer Res; 2002; 22(6B):3737-41. PubMed ID: 12552986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA flow-cytometry on fine needle aspiration cytology of lymph node: how helpful is it?
    Dey P; Saikia UN; Vohra H
    Indian J Pathol Microbiol; 2000 Apr; 43(2):127-30. PubMed ID: 11217267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular DNA content and survival in advanced ovarian carcinoma.
    Pfisterer J; Kommoss F; Sauerbrei W; Renz H; du Bois A; Kiechle-Schwarz M; Pfleiderer A
    Cancer; 1994 Nov; 74(9):2509-15. PubMed ID: 7923008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is DNA aneuploidy a prognostic factor in gastric cancer?
    Omejc M; Repse S; Bracko M
    Acta Chir Hung; 1997; 36(1-4):266-9. PubMed ID: 9408370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneity of salivary gland tumors studied by flow cytometry.
    Tytor M; Gemryd P; Wingren S; Grenko RT; Lundgren J; Lundquist PG; Nordenskjöld B
    Head Neck; 1993; 15(6):514-21. PubMed ID: 8253558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometric evaluation of epithelial ovarian cancer.
    Barnabei VM; Miller DS; Bauer KD; Murad TM; Rademaker AW; Lurain JR
    Am J Obstet Gynecol; 1990 Jun; 162(6):1584-90; discussion 1590-2. PubMed ID: 2360592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors.
    Fu YS; Ro J; Reagan JW; Hall TL; Berek J
    Obstet Gynecol; 1986 Apr; 67(4):478-82. PubMed ID: 3960418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral heterogeneity in DNA ploidy of esophageal squamous cell carcinomas.
    Sasaki K; Murakami T; Murakami T; Nakamura M
    Cancer; 1991 Dec; 68(11):2403-6. PubMed ID: 1933777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor DNA content in the prognosis of colorectal carcinoma.
    Kokal W; Sheibani K; Terz J; Harada JR
    JAMA; 1986 Jun; 255(22):3123-7. PubMed ID: 3702022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA stemline heterogeneity of non-small cell lung carcinomas and differences in DNA ploidy between carcinomas and metastatic nodes.
    Ayabe H; Tomita M; Kawahara K; Tagawa Y; Tsuji H; Akamine S
    Lung Cancer; 1994 Sep; 11(3-4):201-8. PubMed ID: 7812698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometric determination of the DNA content in transitional cell carcinoma of the bladder: predictability of ploidy with regard to pelvic lymph node metastasis.
    Lee SE; Kim YK
    Int J Urol; 1994 Sep; 1(3):232-6. PubMed ID: 7614381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.